Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of "Buy" from Brokerages

Key Points

• Dianthus Therapeutics, Inc. has received a consensus rating of "Buy" from seven analysts, with an average 1-year price target of $54.00.
• The company reported a loss of ($0.88) EPS for the last quarter, missing the consensus estimate by $0.02, and had revenue significantly below expectations.
• Prominent hedge funds have increased their stakes in Dianthus Therapeutics, with institutional investors owning 47.53% of the company's stock.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been assigned an average rating of "Buy" from the seven analysts that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $54.00.

Several equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. William Blair began coverage on shares of Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an "outperform" rating on the stock. Robert W. Baird dropped their target price on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. Finally, Wedbush lifted their target price on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an "outperform" rating in a research report on Thursday, August 21st.

Dianthus Therapeutics Trading Up 7.5%

NASDAQ DNTH traded up $1.84 during trading hours on Wednesday, hitting $26.50. The company's stock had a trading volume of 679,673 shares, compared to its average volume of 359,164. Dianthus Therapeutics has a 52 week low of $13.36 and a 52 week high of $32.27. The company has a market capitalization of $853.04 million, a PE ratio of -8.15 and a beta of 1.46. The company's 50-day simple moving average is $21.27 and its two-hundred day simple moving average is $20.03.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The business had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. Research analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds have recently modified their holdings of DNTH. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $27,000. US Bancorp DE lifted its position in shares of Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock worth $29,000 after buying an additional 1,510 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics in the 4th quarter worth approximately $59,000. GAMMA Investing LLC raised its holdings in shares of Dianthus Therapeutics by 3,030.6% in the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock worth $70,000 after purchasing an additional 3,758 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock worth $80,000 after purchasing an additional 3,317 shares during the period. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.